These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 17214117

  • 1. Intensive lipid-lowering therapy: obvious benefits, possible risks.
    Zimlichman E, Szyper-Kravitz M, Katz U, Shoenfeld Y.
    Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
    [No Abstract] [Full Text] [Related]

  • 2. Lipid-lowering therapy--benefits and risks.
    Abinader EG.
    Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
    [No Abstract] [Full Text] [Related]

  • 3. Lipid-lowering therapy--benefits and risks.
    Shechter M.
    Isr Med Assoc J; 2007 Feb; 9(2):133; author reply 133-4. PubMed ID: 17348492
    [No Abstract] [Full Text] [Related]

  • 4. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May 28; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract] [Full Text] [Related]

  • 5. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T, von Bergmann K.
    MMW Fortschr Med; 2003 Apr 17; 145(16):48-50. PubMed ID: 14606402
    [No Abstract] [Full Text] [Related]

  • 6. [Antilipemic therapy and rhabdomyolysis].
    Paragh G, Balogh Z, Romics L.
    Orv Hetil; 2003 Mar 16; 144(11):515-20. PubMed ID: 12731338
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fatal rhabdomyolysis caused by lipid-lowering therapy.
    Federman DG, Hussain F, Walters AB.
    South Med J; 2001 Oct 16; 94(10):1023-6. PubMed ID: 11702815
    [Abstract] [Full Text] [Related]

  • 10. Fenofibric Acid (trilipix).
    Med Lett Drugs Ther; 2009 May 04; 51(1311):33-4. PubMed ID: 19417718
    [No Abstract] [Full Text] [Related]

  • 11. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.
    Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM.
    Am J Cardiol; 2008 Jun 01; 101(11):1606-13. PubMed ID: 18489938
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Lipid control in the double pack. Combined drugs to achieve the goal].
    MMW Fortschr Med; 2002 Jun 06; 144(23):53. PubMed ID: 12119910
    [No Abstract] [Full Text] [Related]

  • 14. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 06; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 15. Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol?
    Lee T.
    Harv Heart Lett; 2010 Aug 06; 20(12):8. PubMed ID: 20812395
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rosuvastatin--a new lipid-lowering drug.
    Med Lett Drugs Ther; 2003 Oct 13; 45(1167):81-3. PubMed ID: 14534507
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
    Brudi P, Reckless JP, Henry DP, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO.
    Cardiology; 2009 Oct 13; 113(2):89-97. PubMed ID: 19018143
    [Abstract] [Full Text] [Related]

  • 20. Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings.
    Mosshammer D, Lorenz G, Meznaric S, Schwarz J, Muche R, Mörike K.
    Fam Pract; 2009 Apr 13; 26(2):88-95. PubMed ID: 19233960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.